首页> 外文OA文献 >A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

【2h】

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

机译：靶向VEGF受体-2的人单克隆抗体，作为患有先进肝细胞癌患者的一线单疗法的人单克隆抗体的II和生物标志物研究。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Andrew X. Zhu; Richard S. Finn; Mary Mulcahy; Jayne Gurtler; Weijing Sun; Jonathan D. Schwartz; Rita P. Dalal; Adarsh Joshi; Rebecca R. Hozak; Yihuan Xu; Marek Ancukiewicz; Rakesh K. Jain; Francis W. Nugent; Dan G. Duda; Keith Stuart;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular Cancer [J] . ZhuA.X., FinnR.S., MulcahyM., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第23期

机译：雷莫昔单抗（一种靶向VEGF受体2的人单克隆抗体）的II期和生物标志物研究，作为晚期肝细胞癌患者的一线单药治疗
2. Phase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors [J] . Chiorean E. G., Hurwitz H. I., Cohen R. B., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第6期

机译：晚期实体瘤患者每2或3周给药雷莫西单抗（一种靶向血管内皮生长因子受体2的人免疫球蛋白G1单克隆抗体）的I期研究
3. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017) [J] . Chau Ian, Peck-Radosavljevic Markus, Borg Christophe, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：RAMUCILUMAB作为肝癌先进治疗后患有先进肝细胞癌的二线治疗：随机阶段III REACH研究的患者聚焦的结果结果（VOL 81，2017年，PG 17,2017）
4. Characterization of cancer specific human monoclonal IgM antibodies produced by hybridomas derived from a patient with adult T-cell leukemia [C] . T. KAWAHARA, A. ICHIKAWA, Y. KATAKURA, Annual Meeting of the Japanese Association for Animal Cell Technology . 2002

机译：杂交瘤产生的癌症特异性人单克隆IgM抗体的表征衍生自成人T细胞白血病患者的杂交瘤
5. Design, synthesis and validation of Axl-targeted monoclonal antibody probe for microPET imaging of human lung cancer. [D] . Guo, Jiacong. 2013

机译：针对人类肺癌的microPET成像的Axl靶向单克隆抗体探针的设计，合成和验证。
6. A Phase II and Biomarker Study of Ramucirumab a Human Monoclonal Antibody Targeting the VEGF Receptor-2 as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer [O] . Andrew X. Zhu, Richard S. Finn, Mary Mulcahy, -1

机译：雷莫昔单抗（靶向VEGF Receptor-2的人单克隆抗体）的II期和生物标志物研究作为晚期肝细胞癌患者的一线单药治疗
7. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 [O] . Spratlin, Jennifer L., Cohen, Roger B., Eadens, Matthew, 2010

机译：Ramucirumab（IMC-1121B）是针对血管内皮生长因子受体2的完全人免疫球蛋白G1单克隆抗体的I期药理和生物学研究

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

著录项

相似文献

相关主题

期刊订阅